DK3916392T3 - Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter - Google Patents
Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter Download PDFInfo
- Publication number
- DK3916392T3 DK3916392T3 DK21170716.1T DK21170716T DK3916392T3 DK 3916392 T3 DK3916392 T3 DK 3916392T3 DK 21170716 T DK21170716 T DK 21170716T DK 3916392 T3 DK3916392 T3 DK 3916392T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapy
- patients
- methods
- therapeutic benefit
- predicting therapeutic
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16171885 | 2016-05-30 | ||
| EP17728484.1A EP3465214B1 (en) | 2016-05-30 | 2017-05-30 | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3916392T3 true DK3916392T3 (da) | 2024-05-21 |
Family
ID=56116221
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21170716.1T DK3916392T3 (da) | 2016-05-30 | 2017-05-30 | Fremgangsmåder til at forudsige terapeutiske fordele af anti-CD19-behandlingen hos patienter |
| DK17728484.1T DK3465214T3 (da) | 2016-05-30 | 2017-05-30 | Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17728484.1T DK3465214T3 (da) | 2016-05-30 | 2017-05-30 | Fremgangsmåder til forudsigelse af terapeutisk fordel ved anti-cd19-terapi hos patienter |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20190195879A1 (da) |
| EP (2) | EP3916392B1 (da) |
| JP (2) | JP7066639B2 (da) |
| KR (1) | KR102416144B1 (da) |
| CN (2) | CN115932265A (da) |
| AU (1) | AU2017272608B2 (da) |
| BR (1) | BR112018074603A2 (da) |
| CA (1) | CA3025823A1 (da) |
| CY (1) | CY1124768T1 (da) |
| DK (2) | DK3916392T3 (da) |
| EA (1) | EA201892542A1 (da) |
| ES (1) | ES2878156T3 (da) |
| FI (1) | FI3916392T3 (da) |
| HR (1) | HRP20210938T1 (da) |
| HU (1) | HUE054860T2 (da) |
| IL (1) | IL263103B2 (da) |
| LT (2) | LT3465214T (da) |
| MA (2) | MA57021B1 (da) |
| MD (1) | MD3465214T2 (da) |
| MX (2) | MX2018014702A (da) |
| PL (1) | PL3465214T3 (da) |
| PT (2) | PT3465214T (da) |
| RS (2) | RS62155B1 (da) |
| SG (2) | SG10201911958SA (da) |
| SI (1) | SI3465214T1 (da) |
| WO (1) | WO2017207574A1 (da) |
| ZA (1) | ZA201808647B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3962943A1 (en) | 2019-05-03 | 2022-03-09 | MorphoSys AG | Anti-cd19 therapy in patients having a limited number of nk cells |
| CA3158985A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Sequential anti-cd19 therapy |
| JP2023501209A (ja) * | 2019-10-31 | 2023-01-18 | モルフォシス・アーゲー | 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法 |
| CA3204063A1 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ573838A (en) | 1998-08-11 | 2011-01-28 | Biogen Idec Inc | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
| WO2002068414A2 (en) | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| US7109304B2 (en) | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EA200800094A1 (ru) | 2005-06-20 | 2008-06-30 | Медарекс, Инк. | Антитела cd19 и их использование |
| DK2270050T3 (da) | 2005-12-30 | 2013-08-12 | Merck Patent Gmbh | Anti-CD19-antistoffer med nedsat immunogenicitet |
| WO2008022152A2 (en) | 2006-08-14 | 2008-02-21 | Xencor, Inc. | Optimized antibodies that target cd19 |
| PL2066349T3 (pl) | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych |
| DE602007013068D1 (de) | 2006-09-13 | 2011-04-21 | Glycode | Verfahren zur untersuchung der reaktion auf eine behandlung mit einem monoklonalen antikörper |
| US8063187B2 (en) | 2007-05-30 | 2011-11-22 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells |
| RU2476441C2 (ru) | 2007-10-19 | 2013-02-27 | Сиэтл Дженетикс, Инк. | Cd19-связывающие средства и их применение |
| EP2398829A2 (en) | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| AU2011329161A1 (en) | 2010-11-15 | 2013-06-27 | Medimmune, Llc | Combination therapy for B cell lymphomas |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| PT2744826T (pt) * | 2011-08-16 | 2022-05-19 | Morphosys Ag | Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina |
| HUE058350T2 (hu) | 2011-08-16 | 2022-07-28 | Morphosys Ag | Kombinációs terápia, CD19 elleni ellenanyag és nitrogénmustár alkalmazásával |
| EP2791165A4 (en) * | 2011-12-12 | 2015-08-05 | Pikamab Inc | PREDICTING SENSITIVITY TO ANTIBODY MAINTENANCE THERAPY |
| EP3110445A4 (en) * | 2014-02-25 | 2017-09-27 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| CN106794231A (zh) | 2014-06-16 | 2017-05-31 | 赞科股份有限公司 | 用于慢性淋巴细胞性白血病（cll）的治疗 |
| US10969391B2 (en) | 2014-07-11 | 2021-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing hematological cancers |
-
2017
- 2017-05-30 DK DK21170716.1T patent/DK3916392T3/da active
- 2017-05-30 MA MA57021A patent/MA57021B1/fr unknown
- 2017-05-30 SG SG10201911958SA patent/SG10201911958SA/en unknown
- 2017-05-30 RS RS20210893A patent/RS62155B1/sr unknown
- 2017-05-30 LT LTEP17728484.1T patent/LT3465214T/lt unknown
- 2017-05-30 PL PL17728484T patent/PL3465214T3/pl unknown
- 2017-05-30 IL IL263103A patent/IL263103B2/en unknown
- 2017-05-30 EP EP21170716.1A patent/EP3916392B1/en active Active
- 2017-05-30 SI SI201730823T patent/SI3465214T1/sl unknown
- 2017-05-30 LT LTEP21170716.1T patent/LT3916392T/lt unknown
- 2017-05-30 US US16/305,482 patent/US20190195879A1/en not_active Abandoned
- 2017-05-30 ES ES17728484T patent/ES2878156T3/es active Active
- 2017-05-30 FI FIEP21170716.1T patent/FI3916392T3/fi active
- 2017-05-30 CN CN202211271570.5A patent/CN115932265A/zh active Pending
- 2017-05-30 CN CN201780033793.9A patent/CN109313194B/zh active Active
- 2017-05-30 WO PCT/EP2017/063045 patent/WO2017207574A1/en unknown
- 2017-05-30 MX MX2018014702A patent/MX2018014702A/es unknown
- 2017-05-30 EA EA201892542A patent/EA201892542A1/ru unknown
- 2017-05-30 BR BR112018074603-7A patent/BR112018074603A2/pt unknown
- 2017-05-30 PT PT177284841T patent/PT3465214T/pt unknown
- 2017-05-30 JP JP2018562324A patent/JP7066639B2/ja active Active
- 2017-05-30 AU AU2017272608A patent/AU2017272608B2/en active Active
- 2017-05-30 MD MDE20190405T patent/MD3465214T2/ro unknown
- 2017-05-30 DK DK17728484.1T patent/DK3465214T3/da active
- 2017-05-30 PT PT211707161T patent/PT3916392T/pt unknown
- 2017-05-30 HU HUE17728484A patent/HUE054860T2/hu unknown
- 2017-05-30 CA CA3025823A patent/CA3025823A1/en active Pending
- 2017-05-30 SG SG11201810159TA patent/SG11201810159TA/en unknown
- 2017-05-30 RS RS20240525A patent/RS65540B1/sr unknown
- 2017-05-30 KR KR1020187038026A patent/KR102416144B1/ko active IP Right Grant
- 2017-05-30 EP EP17728484.1A patent/EP3465214B1/en active Active
- 2017-05-30 MA MA45124A patent/MA45124B1/fr unknown
-
2018
- 2018-11-28 MX MX2021014963A patent/MX2021014963A/es unknown
- 2018-12-20 ZA ZA2018/08647A patent/ZA201808647B/en unknown
-
2021
- 2021-06-11 HR HRP20210938TT patent/HRP20210938T1/hr unknown
- 2021-07-13 CY CY20211100629T patent/CY1124768T1/el unknown
-
2022
- 2022-04-27 JP JP2022072884A patent/JP7511806B2/ja active Active
- 2022-05-25 US US17/824,266 patent/US20220283166A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3294770T3 (da) | Terapeutiske og diagnostiske fremgangsmåder til cancer | |
| DK3277842T3 (da) | Fremgangsmåder til at behandle kræftpatienter med farnesyl-transferase-inhibitorer | |
| DK3698847T3 (da) | Magnetisk stimuleringsudstyr til terapeutisk behandling | |
| DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
| DK3024497T3 (da) | Fremgangsmåder og præparater til behandling af hjernesygdomme | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3289080T3 (da) | Genterapi til autosomalt dominante sygdomme | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3182901T3 (da) | System og fremgangsmåde til ikke-invasiv analyse af kropsfluider | |
| DK3178849T3 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3442580T3 (da) | Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme | |
| DK2964327T3 (da) | Anordninger og fremgangsmåder til multifokal ultralydsterapi | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3094640T3 (da) | Fremgangsmåder til steril kromatografi og fremstilling | |
| DK3253412T3 (da) | Anti-cd40l-antistoffer og fremgangsmåder til behandling af cd40l-forbundne sygdomme eller forstyrrelser | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme |